BioAge CEO and leadership

Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. Eric completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Dr. Goldstein brings over 20 years of strategic financial and operational experience within the healthcare sector. He currently serves as the Chief Financial Officer and Chief Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRy-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer. Dr. Goldstein was previously Chief Executive Officer of RIGImmune. Prior to that he served as the Chief Financial Officer at Schrödinger, LLC from 2017 to 2018. Dr. Goldstein held various leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between 2014 and 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc., raising over $250 million in equity financings, facilitating company partnership transactions and participating in the M&A process when Vicuron was acquired by Pfizer, Inc. for $1.9 billion. Prior to joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures.

Dr. Goldstein currently serves on the board of Directors of NeuBase Therapeutics (Nasdaq: NBSE) and Gain Therapeutics (Nasdaq: GANX). He previously served as a director for ADMA Biologics, Loxo Oncology, Esperion Therapeutics, Duranta Therapeutics, Cempra and a number of private companies. He received a Bachelor of Science in biological sciences from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.

Paul leads the clinical development of BIOAGE's pipeline of therapies that target aging. Paul is an experienced pharma and biotech executive with extensive experience in small molecules, biologics and oligonucleotide therapeutics and has advanced dozens of compounds from discovery through approval. He has worked in multiple therapeutic areas where he was intimately involved with discovery, preclinical and clinical development, regulatory and marketing. Prior to joining BIOAGE, Paul was Executive VP Research and Development at miRagen from 2016-2020. He was Senior VP of Research and Development and CMO at XOMA. Ltd from 2011 - 2015, CEO of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009, and President and CEO of Critical Therapeutics, Inc. from 2002 to 2007.

Ms. Neale joined as SVP of Development Operations in 2018. From 2014 to 2017 she served as VP of Clinical Operations and Data Assessment at XOMA where she led the functions responsible for development, execution and analysis of the early phase and global phase 3 programs. From 2007 to 2014 she was VP of Clinical Operations at Biotie Therapies leading the global clinical operations strategy and data deliverables for 5 molecules. From 1995 to 2007 Ms. Neale was a consultant and founding partner in Winpharm Associates, LLC, leading development strategies for US and Canadian clients in multiple therapeutic areas, including dermatology, immunology, oncology, enzyme disorders, CNS, and endocrinology. From 1993 to 1995 Ms. Neale’s responsibilities included overseeing 2 successful IND submissions at Titan Pharmaceuticals. From 1989 to 1993 Ms. Neale held various positions of increasing responsibility at Syntex Inc., on the phase 3 approvals and line extensions for Cellcept, Synarel and Cardene. Prior to 1993 Ms. Neale was a charge nurse in transplant and critical care hospital units.

Ms. Neale holds a B.S. degree in Nursing from the University of Minnesota.

BJ leads cross-functional strategic and operational projects at BioAge, partnering closely with the company's executive team. Previously, BJ was a Manager in the Life Sciences practice at L.E.K. Consulting, where he supported biopharma and diagnostics clients in growth strategy and M&A. Key accomplishments at L.E.K. include diligence efforts that culminated in a ~$75B acquisition-one of the largest healthcare transactions in history-followed by integration planning and development of a roadmap to immunology leadership for the NewCo. BJ received an undergraduate degree in Molecular Biology from Princeton University and a PhD in Molecular & Medical Pharmacology from the UCLA School of Medicine, where his research resulted in a first-author publication in Cell.

Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. Eric completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Dr. Goldstein brings over 20 years of strategic financial and operational experience within the healthcare sector. He currently serves as the Chief Financial Officer and Chief Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRy-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer. Dr. Goldstein was previously Chief Executive Officer of RIGImmune. Prior to that he served as the Chief Financial Officer at Schrödinger, LLC from 2017 to 2018. Dr. Goldstein held various leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between 2014 and 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc., raising over $250 million in equity financings, facilitating company partnership transactions and participating in the M&A process when Vicuron was acquired by Pfizer, Inc. for $1.9 billion. Prior to joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures.

Dr. Goldstein currently serves on the board of Directors of NeuBase Therapeutics (Nasdaq: NBSE) and Gain Therapeutics (Nasdaq: GANX). He previously served as a director for ADMA Biologics, Loxo Oncology, Esperion Therapeutics, Duranta Therapeutics, Cempra and a number of private companies. He received a Bachelor of Science in biological sciences from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.

Eric leads BIOAGE’s human cohort partnerships and computational efforts to discover and prioritize drug targets for human aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. Eric completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.